Human P450 metabolism of warfarin

被引：655

作者：

Kaminsky, LS ^{[1
]}

Zhang, ZY ^{[1
]}

机构：

[1] SUNY ALBANY,SCH PUBL HLTH,DEPT ENVIRONM HLTH & TOXICOL,ALBANY,NY 12201

来源：

PHARMACOLOGY & THERAPEUTICS | 1997年 / 73卷 / 01期

关键词：

human metabolism; R-warfarin; S-warfarin; cytochrome P450; CYP3A4; CYP2C9;

D O I：

10.1016/S0163-7258(96)00140-4

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

The anticoagulant drug warfarin occurs as a pair of enantiomers that are differentially metabolized by human cytochromes P450 (CYP). R-warfarin is metabolized primarily by CYP1A2 to 6 and 8-hydroxywarfarin, by CYP3A4 to 10-hydroxywarfarin, and by carbonyl reductases to diastereoisomeric alcohols. S-warfarin is metabolized primarily by CYP2C9 to 7-hydroxywarfarin. Potential warfarin-drug interactions could occur with any of a very wide range of drugs that are metabolized by these P450s, and a number of such interactions have been reported. The efficacy of warfarin is affected primarily when metabolism of S-warfarin is altered. Copyright (C) 1996 Elsevier Science Inc.

引用

页码：67 / 74

页数：8

共 56 条

[1]

ABERNETHY DR, 1991, J PHARMACOL EXP THER, V257, P411

[2]

PHENYLBUTAZONE-WARFARIN INTERACTION IN MAN - FURTHER STEREOCHEMICAL AND METABOLIC CONSIDERATIONS [J].

BANFIELD, C ;

OREILLY, R ;

CHAN, E ;

ROWLAND, M .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (06) :669-675

[3]

THE EFFECT OF CIPROFLOXACIN ON THEOPHYLLINE PHARMACOKINETICS IN HEALTHY-SUBJECTS [J].

BATTY, KT ;

DAVIS, TME ;

ILETT, KF ;

DUSCI, LJ ;

LANGTON, SR .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (03) :305-311

[4]

GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19 [J].

BERTILSSON, L .

CLINICAL PHARMACOKINETICS, 1995, 29 (03) :192-209

[5]

CATALYTIC ACTIVITIES OF HUMAN LIVER CYTOCHROME-P-450-IIIA4 EXPRESSED IN SACCHAROMYCES-CEREVISIAE [J].

BRIAN, WR ;

SARI, MA ;

IWASAKI, M ;

SHIMADA, T ;

KAMINSKY, LS ;

GUENGERICH, FP .

BIOCHEMISTRY, 1990, 29 (51) :11280-11292

[6]

INTERPHENOTYPE DIFFERENCES IN DISPOSITION AND EFFECT ON GASTRIN-LEVELS OF OMEPRAZOLE - SUITABILITY OF OMEPRAZOLE AS A PROBE FOR CYP2C19 [J].

CHANG, M ;

TYBRING, G ;

DAHL, ML ;

GOTHARSON, E ;

SAGAR, M ;

SEENSALU, R ;

BERTILSSON, L .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (05) :511-518

[7]

GOTOH O, 1992, J BIOL CHEM, V267, P83

[8]

HEIMARK LD, 1984, J MED CHEM, V27, P1092, DOI 10.1021/jm00374a027

[9]

THE MECHANISM OF THE WARFARIN-RIFAMPIN DRUG-INTERACTION IN HUMANS [J].

HEIMARK, LD ;

GIBALDI, M ;

TRAGER, WF ;

OREILLY, RA ;

GOULART, DA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (04) :388-394

[10]

HUMAN LIVER MICROSOMAL METABOLISM OF THE ENANTIOMERS OF WARFARIN AND ACENOCOUMAROL - P450 ISOZYME DIVERSITY DETERMINES THE DIFFERENCES IN THEIR PHARMACOKINETICS [J].

HERMANS, JJR ;

THIJSSEN, HHW .

BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (01) :482-490

← 1 2 3 4 5 6 →